)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Divi’s Laboratories
Divi’s Laboratories (DIVISLAB) investor relations material
Divi’s Laboratories Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary1 Aug, 2026
Executive summary
Q1 FY 2027 saw resilient business performance despite challenging global trade and sourcing conditions, with strong execution in custom synthesis and stable generics volumes.
Consolidated total income for Q1 FY 2027 was INR 3,144 crores, up from INR 2,529 crores year-over-year.
Profit before tax rose to INR 1,180 crores from INR 733 crores, and profit after tax increased to INR 902 crores from INR 545 crores year-over-year.
Standalone total income was INR 3,037 crores, with profit after tax at INR 891 crores for the quarter.
Standalone revenue grew 10% on a constant currency basis; exports made up 90% of revenue, with Europe and North America accounting for 75% of exports.
Financial highlights
Standalone revenue from operations for Q1 FY2026-27 was INR 2,974 crores, up from INR 2,357 crores year-over-year.
Standalone profit before tax was INR 1,165 crores, up from INR 747 crores year-over-year.
Standalone earnings per share (EPS) for the quarter was INR 33.55, compared to INR 20.95 in Q1 last year.
Consolidated EPS for the quarter was INR 33.95, up from INR 20.49 year-over-year.
Forex loss of INR 7 crores in Q1 FY2026-27, compared to a gain of INR 39 crores in Q1 last year.
Outlook and guidance
Management reiterated expectations for double-digit revenue growth for the full year, with lumpiness possible due to regulatory approvals and project mix.
Gross and EBITDA margins are expected to be comparable or slightly better than last year, but quarterly fluctuations are anticipated.
Board approved the unaudited financial results for the quarter ended June 30, 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Divi’s Laboratories
- PAT rose 39.16% as expansion plans advanced and R&D write-offs weighed on reported profit.DIVISLAB
Q4 01/02 - Sales and PAT grew strongly as Chippada launched and exports drove 91% of turnover.DIVISLABQ4 02/03
- Sales grew 15%, but higher costs and taxes reduced FY05 earnings.DIVISLABQ4 04/05
- FY04 sales and PAT grew strongly as exports and API capacity expanded.DIVISLABQ4 03/04
- Export-led growth drove 90% sales growth as major capacity expansion came online.DIVISLABQ4 06/07
- Sales and PAT grew as exports and capacity expansion drove the FY07 growth agenda.DIVISLABQ4 05/06
- FY08 sales rose 43% and PAT 84% as capacity expanded and exports dominated.DIVISLABQ4 07/08
- FY09 growth persisted, but FX losses, destocking and disputed SEZ tax clouded results.DIVISLABQ4 08/09
- Destocking cut FY10 sales 22%; capacity expansion targets the recovery.DIVISLABQ4 09/10
- Net sales rose 41%, PAT 27%; Rs.200 crore SEZ expansion entered trial runs.DIVISLABQ4 10/11
Next Divi’s Laboratories earnings date
Q2 26/276 Nov, 2026
Divi’s Laboratories
Next Divi’s Laboratories earnings date
Q2 26/276 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Divi’s Laboratories Limited manufactures active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients for global pharmaceutical companies. The company specializes in custom synthesis and contract manufacturing for generic and branded drugs. Divi’s Laboratories serves customers in regulated markets including the United States and Europe. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.